The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse Collection of efficacy and safety data of chinese patients who have received Faslodex 250mg treatmen
- collapse A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults with Gastrointestinal Adenocarcinomas
- collapse A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- collapse A Phase 1, Dose-Escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects with Relapsed or Refractory Advanced B-Cell Malignancies
- collapse A Phase 1, Multicenter, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability and Antitumor Activity of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors I and II, in Subjects with Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
- collapse A Phase 1b/2 Randomized Study of MEDI-575 in Combination with Carboplatin plus Paclitaxel versus Carboplatin plus Paclitaxel Alone in Adult Subjects with Previously Untreated, Advanced Non-Small Cell Lung Cancer
- collapse A Phase 1b/2 Randomized Study of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC)
- collapse A Phase 1b/2, Open-Label, Randomized Study of MEDI-573 in Combination with Sorafenib versus Sorafenib Alone in Adult Subjects with Unresectable or Metastatic Hepatocellular Carcinoma
- collapse A Phase 2 Study of MEDI-575 in Adult Subjects with Recurrent Glioblastoma Multiforme
- collapse A Phase I, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI0639 in Adult Subjects with Advanced Solid Tumors
